Liberini Virginia, Huellner Martin W, Grimaldi Serena, Finessi Monica, Thuillier Philippe, Muni Alfredo, Pellerito Riccardo E, Papotti Mauro G, Piovesan Alessandro, Arvat Emanuela, Deandreis Désirée
Nuclear Medicine Unit, Department of Medical Sciences, University of Turin, 10126 Turin, Italy.
Department of Nuclear Medicine, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland.
Diagnostics (Basel). 2020 Dec 12;10(12):1083. doi: 10.3390/diagnostics10121083.
The NETTER-1 study has proven peptide receptor radionuclide therapy (PRRT) to be one of the most effective therapeutic options for metastatic neuroendocrine tumors (NETs), improving progression-free survival and overall survival. However, PRRT response assessment is challenging and no consensus on methods and timing has yet been reached among experts in the field. This issue is owed to the suboptimal sensitivity and specificity of clinical biomarkers, limitations of morphological response criteria in slowly growing tumors and necrotic changes after therapy, a lack of standardized parameters and timing of functional imaging and the heterogeneity of PRRT protocols in the literature. The aim of this article is to review the most relevant current approaches for PRRT efficacy prediction and response assessment criteria in order to provide an overview of suitable tools for safe and efficacious PRRT.
NETTER-1研究已证明肽受体放射性核素治疗（PRRT）是转移性神经内分泌肿瘤（NET）最有效的治疗选择之一，可改善无进展生存期和总生存期。然而，PRRT反应评估具有挑战性，该领域的专家尚未就评估方法和时间达成共识。这个问题归因于临床生物标志物的敏感性和特异性欠佳、生长缓慢的肿瘤形态学反应标准的局限性以及治疗后坏死变化、缺乏功能成像的标准化参数和时间，以及文献中PRRT方案的异质性。本文的目的是综述当前最相关的PRRT疗效预测方法和反应评估标准，以便概述适用于安全有效的PRRT的工具。
